

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-052024-000839

Date: 30/05/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Secukinumab
- Ustekinumab

Response

Q1. In the 3 months Feb24-Apr24, the following number of patients were issued the listed biologic drugs by the Dermatology department (for any medical condition):

<i>Drug</i>	<i>PT Count</i>
<i>Adalimumab - Humira</i>	<i>7</i>
<i>Adalimumab Biosimilar</i>	<i>107</i>
<i>Apremilast</i>	<i>1</i>
<i>Bimekizumab</i>	<i>11</i>
<i>Brodalumab</i>	<i>1</i>
<i>Certolizumab</i>	<i>5</i>
<i>Deucravacitinib</i>	<i>1</i>
<i>Dimethyl fumarate</i>	<i>0</i>
<i>Etanercept - Enbrel</i>	<i>1</i>
<i>Etanercept Biosimilar</i>	<i>0</i>
<i>Guselkumab</i>	<i>19</i>
<i>Infliximab - Remicade</i>	<i>0</i>
<i>Infliximab Biosimilar</i>	<i>2</i>
<i>Ixekizumab</i>	<i>1</i>
<i>Risankizumab</i>	<i>18</i>
<i>Secukinumab</i>	<i>62</i>
<i>Tildrakizumab</i>	<i>22</i>
<i>Ustekinumab</i>	<i>14</i>

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Bimekizumab**
- **Certolizumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Secukinumab**
- **Ustekinumab**

Pharmacy records do not include indication data in a reportable format. We cannot therefore, answer Q2 without looking up individual patient records which would take us beyond the appropriate limit set out in section 18 of the Freedom of Information Act.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust